ArticlePsychopharmacology2026
Beyond cannabis use severity: associations of cannabis product type with sleep quality and mental health.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePeople who use cannabis often report using it to improve sleep and/or manage mental health symptoms. Cannabis products differ in their typical cannabinoid composition, particularly in their relative THC and CBD content, which may impact health outcomes differently.
objectivesThis naturalistic study investigated associations between cannabis use and related problems, sleep quality, and symptoms of anxiety/depression among people who use cannabis near daily and examined the role of cannabis product types.
methodsDanish adults who reported using cannabis on 26.15 ± 6.23 days/month completed an online survey (197 participants; 64.5% men, M
resultsSeverity of cannabis use and related problems, as indexed by CUDIT-R, was associated with poorer sleep quality and higher levels of anxiety/depression symptoms, which was not moderated by cannabis product type. Product type explained additional variance in sleep quality, but not in anxiety/depression symptoms. Individuals who reported using hash only and multiple THC-dominant product types exhibited poorer sleep quality compared with those who used flower only, independent of severity of cannabis use and related problems.
conclusionsSeverity of cannabis use and related problems was linked with sleep and mental health problems, and product type did not alter the strength of these associations. Use of hash or multiple THC-dominant product was associated with more sleep problems than use of flower, adding to the literature showing that products with greater THC concentration are more harmful. Longitudinal studies are needed to establish causal relationships.
Indexed as
Identifiers
42324387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.